Even AbbVie CEO can't confirm Rinvoq's sales as FDA mulls JAK label

When the FDA dropped the bombshell that it would add more safety warnings and restrict the use of JAK inhibitors, industry watchers began weighing the impact on a key player: AbbVie’s Rinvoq. But right now, even AbbVie’s CEO isn’t sure how much damage the update will do.